Monitoring of therapy for inflammatory bowel disease

Digestion

Volumn 86, Issue SUPPL. 1, 2012, Pages 1-5

  Burri, Emanuel ^a   Beglinger, Christoph ^a   Lehmann, Frank Serge ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

C reactive protein; Calprotectin; Inflammatory bowel disease; Monitoring of treatment response

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; ENDOTHELIN 1; GHRELIN; INFLIXIMAB; INTERLEUKIN 6; LACTOFERRIN; NITRIC OXIDE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; CANCER SCREENING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLONOSCOPY; COLORECTAL CARCINOMA; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; ENTERITIS; HUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEROID THERAPY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BIOPSY; C-REACTIVE PROTEIN; COLONOSCOPY; DRUG MONITORING; FECES; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84867508196     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000341953     Document Type: Article

References (36)

1. Lewis JD: The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-1826.e2
2. Saverymuttu SH: Clinical remission in Crohn's disease-assessment using faecal 111 in granulocyte excretion. Digestion 1986; 33:74-79.
3. D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC: Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008; 103: 2007-2014.
4. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF: Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7:15-29.
5. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterolo-gy 2010; 138: 463-468.
6. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P: Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15:1295-1301.
7. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E, European Crohn's and Colitis Organization: European Evidence-Based Consensus on the Management of Ul-cerative Colitis: special situations. J Crohns Colitis 2008; 2:63-92.
8. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, Group AIS: Maintenance inflixi mab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
9. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14:1660-1666.
10. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R: Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileo-colonic Crohn's disease. A prospective mul-ticentre study of 121 cases. Groupe d'Etudes Thérapeutiques des Affections Inflamma-toires Digestives. Gut 1994; 35: 231-235.
11. Sipponen T, Savilahti E, Karkkainen P, Kol-ho KL, Nuutinen H, Turunen U, Farkkila M: Fecal calprotectin, lactoferrin, and endo-scopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inf lamm Bowel Dis 2008; 14: 1392-1398.
12. Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, Pfefferkorn M, Rosh J, Kay M, Crandall W, Keljo D, Otley AR, Kugathasan S, Carvalho R, Oliva-Hemker M, Langton C, Mamula P, Bousvaros A, LeLeiko N, Griffiths AM, Pediatric IBDCRG: Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI). Inflamm Bowel Dis 2009; 15:1218-1223.
13. Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH: Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepa-tol 2011; 26: 1114-1122.
14. Lonnkvist MH, Theodorsson E, Holst M, Ljung T, Hellstrom PM: Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol 2011; 46:420-427.
15. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, Group IS: C-re-active protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008; 57: 1518-1523.
16. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F: The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 10:401-405.
17. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelck-mans P, Reynaert H, D'Haens G, Malaise M, Belaiche J: A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-824.
18. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van De-venter S, Goldblum R, Despain D, Hogge GS, Rutgeerts P, International Efficacy of Natali-zumab as Active Crohn's Therapy Trial Group, Evaluation of Natalizumab as Continuous Therapy Trial Group: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925.
19. Reinisch W, Wang Y, Oddens BJ, Link R: C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012; 35: 568-576.
20. Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A, Horvath G, Toth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovasz BD, Vegh Z, Golovics PA, Szathmari M, Papp M, Lakatos PL, Hungarian IBDSG: Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of ada-limumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011; 34: 911-922.
21. Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, Ballet V, Noman M, Hoffman I, van Assche G, Rutgeerts PJ, van Steen K, Vermeire S: Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroen-terol Hepatol 2011; 9: 421-427.e1.
22. Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, Daniel F, Beaugerie L, Cosnes J: Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103:637-642.
23. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP: Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905-910.
24. Yamamoto-Furusho JK, Camacho-Escobe-do J, Tellez-Avila F, Barreto R: Serum levels of beta2 microglobulin and ultrasensitive C-reactive protein as markers of histological activity in ulcerative colitis (article in Spanish). Gac Med Mex 2010; 146:31-35.
25. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rut-geerts P: Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inf lamm Bowel Dis 2012, E-pub ahead of print.
26. Rutgeerts P, Vermeire S, Van Assche G: Mu-cosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 453-455.
27. Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG, Arnott ID, Satsangi J: Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009; 104:673-678.
28. Casellas F, Borruel N, Antolin M, Varela E, Torrejon A, Armadans L, Guarner F, Mal-agelada JR: Fecal excretion of deoxyribonu-cleic acid in long-term follow-up of patients with inactive ulcerative colitis. Inflamm Bowel Dis 2007; 13: 386-390.
29. Roseth AG, Aadland E, Grzyb K: Normalization of faecal calprotectin: a predictor of mu-cosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39:1017-1020.
30. Molander P, AfBjorkesten CG, Mustonen H, Haapamaki J, Vauhkonen M, Kolho KL, Farkkila M, Sipponen T: Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha block ing agents. Inf lamm Bowel Dis 2012, E-pub ahead of print.
31. Hamalainen A, Sipponen T, Kolho KL: Inf-liximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011; 17: 5166-5171.
32. Kolho KL, Raivio T, Lindahl H, Savilahti E: Fecal calprotectin remains high during glu-cocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006; 41:720-725.
33. Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehm-ann FS: Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012; 12: 5.
34. Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, Razaire S, de Ledinghen V, Zerbib F: Prediction of Crohn's disease relapse with faecal calprotectin in inf liximab responders: a prospective study. Aliment Pharmacol Ther 2011; 34: 462-469.
35. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ: Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105:1133-1139.
36. Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP: Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012.